Intracameral phenylephrine: the answer to floppy iris syndrome?

Article

Intracameral phenylephrine is a straightforward and effective way to prevent the effects of floppy iris syndrome in patients taking systemic tamsulosin and undergoing cataract surgery.

Intracameral phenylephrine is a straightforward and effective way to prevent the effects of floppy iris syndrome in patients taking systemic tamsulosin and undergoing cataract surgery, according to a study published in the March issue of Eye.

Avinash Gurbaxani and Richard Packard from the King Edward VII Hospital, Berkshire, UK, examined seven patients who were receiving systemic tamsulosin for benign prostatic hypertrophy. Each subject was given intracameral phenylephrine before capsulorhexis during cataract surgery.

The authors observed that there was a significant reduction in the mobility of the iris, reduction in the expected fluttering and sustained papillary dilation.

The results of this study suggest that intracameral phenylephrine can be a useful tool for preventing the effects of floppy iris syndrome in patients receiving systemic tamsulosin while undergoing cataract surgery.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.